{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-009935","form_type":"8-K","ticker":"FNCHQ","cik":"0001733257","company_name":"Finch Therapeutics Group, Inc.","filed_at":"2022-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.051183+00:00","generated_at":"2026-06-25T15:10:11.098074+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Finch Therapeutics reports Q1 net loss of $24.6M; FDA lifts clinical hold on CP101","bullets":["FDA lifted clinical hold on CP101 IND; Phase 3 PRISM4 enrollment expected in H2 2022.","Q1 2022 net loss $24.6M vs $14.0M in Q1 2021; revenue fell due to Takeda amendment.","Secured $55M debt facility from Hercules Capital; $15M drawn at closing.","Workforce reduced ~20% to focus on CDI, ASD, and Takeda-partnered IBD programs.","Cash and equivalents $106.9M as of March 31, 2022; runway into Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-009935","json":"https://secwatch.observer/filing/0000950170-22-009935.json","markdown":"https://secwatch.observer/filing/0000950170-22-009935.md","text":"https://secwatch.observer/filing/0000950170-22-009935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022009935/0000950170-22-009935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733257/000095017022009935/fnch-20220516.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T15:10:11.098074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}